Abstract: The subject invention encompasses methods for the prevention and treatment of a human or lower animal subject having a gastrointestinal disorder caused or mediated by algae and/or cyanobacteria comprising administering bismuth to the subject.

Abstract: Compositions for oral administration for the treatment of gastric disorders comprising histamine H.sub.2 -receptor antagonist, and antacid, optimally buffered to promote local absorption of the H.sub.2 -receptor antagonist, wherein the quantity of H.sub.2 -receptor antagonist per unit dosage form is less than 25 mg.

Abstract: Compositions for oral administration for the treatment of gastric disorders comprising histamine H.sub.2 -receptor antagonist and antacid, optionally buffered to promote local absorption of the H.sub.2 -receptor antagonist, wherein the quantity of H.sub.2 -receptor antagonist per unit dosage form is less than 25 mg.

Abstract: The present invention is directed to a method for the treatment of Helicobacter pylori infection wherein a composition containing protease and an antibacterial agent as active ingredients, which can remove Helicobacter pylori from a stomach at high probability without causing side effects or the occurrence of resistant bacteria, and which can treat and prevent peptic ulcer caused by Helicobacter pylori infection and can prevent the recurrence of peptic ulcer is employed.

Abstract: Method for the treatment of human and lower animals having an infectious gastrointestinal disorder, comprising the step of administering from about 50 to about 5000 milligrams of bismuth to said subject, per day, for from 3 to 56 days. Preferred processes also include a step for performing a diagnostic step on the subject for detection of campylobacter-like organism infection of the subject.

Abstract: An apparatus and process for administering minerals to the human body by mixing pre-selected particulated minerals with graphite and coal tar to form a bar (10a), vaporizing the bar (10a) to form a mineral rich vapor, and directing the vapor to a patient's skin using an enclosure (30).

Abstract: A method is disclosed for preventing the recurrence of duodenal ulcer associated with Campylobacter pylori (Helicobacter pylori) infection in a patient suffering from duodenal ulcer disease associated with Campylobacter pylori infection by administering a pharmaceutically acceptable bismuth compound, a first antibiotic selected from the group consisting of tetracycline and penicillins, and a second antibiotic which is metronidazole.

Abstract: The invention provides a novel antibacterial compound and a process for producing it. Futhermore, the invention provides a novel antibacterial polymer composite comprising a polymer and the antimicrobial compositon.

Abstract: The present invention relates to pharmaceutical compositions useful for treating or preventing gastrointestinal disorders. These compositions comprise a campylobacter-inhibiting antimicrobial agent such as nitrofurantoin and bismuth subsalicylate, and a histamine-2 receptor blocking anti-secretory agent such as cimetidine.The present invention further relates to methods for treating or preventing gastrointestinal disorders in humans or lower animals by administering a campylobacter-inhibiting antimicrobial agent and a histamine-2 receptor blocking anti-secretory agent.

Abstract: The present invention relates to pharmaceutical compositions useful for treating or preventing gastrointestinal disorders. These compositions comprise a bismuth-containing agent, preferably a campylobacter-inhibiting bismuth-containing agent such as bismuth subsalicylate and bismuth subcitrate, and a histamine-2 receptor blocking anti-secretory agent such as cimetidine.The present invention further relates to methods for treating or preventing gastrointestinal disorders in humans or lower animals by administering a bismuth-containing agent and a histamine-2 receptor blocking anti-secretory agent.

Abstract: A process for making a bismuth-containing solid dose form composition is described which includes an agglomeration step with binder in a high shear mixer.

Abstract: A silica gel based heat-resistant and weatherproof antimicrobial composition having an aluminosilicate layer on the surfaces of pores in the silica gel as substituted by silver and an optional antimicrobial metal, said composition containing ion-exchangeable metals that are chiefly an alkali metal and that are present in an amount of up to 2.57 mmol per gram of said composition on an anhydrous basis.

Abstract: Methods, for the treatment of humans and lower animal subjects having a gastrointestinal disorder, comprising administering bismuth and administering an antimicrobial. From about 50 to about 5000 milligrams of bismuth are administered, per day, for from 3 to 56 days. A safe and effective amount of antimicrobial is administered for from 1 to 21 days. Preferred processes also include a step for performing a diagnostic test on the subject for detection of a campylobacter-like organism infection of the subject. The invention also provides compositions containing a safe and effective amount of bismuth and a safe and effective amount of antimicrobial.

Abstract: The present invention provides a novel antimicrobial composition and a process for preparing the composition which composition is useful as antimicrobial and/or bactericidal material. The antimicrobial composition of the invention comprises silica gel and an antimicrobial coat of aluminosilicate on the surface of the silica gel, said composition having a pore volume of at least 0.3 cm.sup.3 /g and a specific surface area of at least 100 m.sup.2 /g. The aluminosilicate coat consists of either partial or complete substitution of ion-exchangeable metal ion (M) in aluminosilicate solid particles represented by the formulaxM.sub.2/n O.Al.sub.2 O.sub.3.ySiO.sub.2.zH.sub.2 O,wherein x and y represent the numbers of molecules of the metal oxide and silicon dioxide, respectively, M is an ion-exchangeable metal, n is the atomic valence of M, and z is the number of molecules of water.

Abstract: This invention provides a recipe for making a detoxification medicine named DTS (Deities) for curing drug addiction. This DTS (Deities) medicine comprises no narcotic but mainly is made up by several kinds of effective ingredients of biological substances refined from various natural herbs and bioproducts. Drug addicts can be weaned and cured safely from addiction induced by Heroin, Cocaine, Morphine, Amphetamines, Hemp or Opium, and other substances within 7-30 days, by means of DTS (Deities) which can get rid of drug poisons present in an addict's blood and marrow. Further, DTS (Deities) can also be used to clear away tobacco tar and nicotine deposits so that it serves to wean from cigarette smoking as well.

Abstract: A method is disclosed for preventing recurrence of duodenal ulcer associated with Campylobacter pylori infection in a patient suffering from duodenal ulcer disease associated with Campylobacter pylori infection by administering a pharmaceutically acceptable bismuth compound; a first antibiotic selected from the group consisting of tetracycline and penicillins and second antibiotic which is metronidazole.

Abstract: A contrast medium-containing tube is provided which is a thermoplastic resin tube incorporated with a white bismuth compound composed mainly of bismuth oxide containing 70-85 wt % bismuth and having a particle diameter substantially smaller than 20 .mu.m. This contrast medium-containing tube looks white and remains white in appearance over a long period of time. It is easy to carry out extrusion molding for producing this contrast medium-containing tube.

Abstract: Oral pharmaceutical compositions in unit dosage form suitable for swallowing (especially capsules) comprising a safe and effective amount of a soluble bismuth-containing pharmaceutical agent (preferably a pharmaceutically-acceptable salt suitable for oral co-administration of bismuth and an H.sub.2 receptor blocking anti-secretory agent), and optionally one or more pharmaceutically-acceptable carrier materials, wherein the packing density of the dosage unit is less than about 1 g/ml.

Abstract: A tube comprises a wall formed from thermoplastic material. The wall is provided with an X-ray opaque agent comprised of a white bismuth compound mixture of bismuth oxide and a white bismuth salt such as bismuth nitrate and bismuth sulfate, the bismuth compound mixture having a bismuth content of 83 to 88% by weight.

Abstract: Microbially-stable liquid pharmaceutical suspensions for oral administration comprising a bismuth-containing pharmaceutical agent, benzoic acid, sorbic acid, a suspension system and water, and wherein said compositions have a pH within the range of from about 3.0 to about 5.5. These compositions are efficacious, and have good aesthetics and good storage stability.

Abstract: A process for producing an effective anti-ulcer preparation in the form of a dry powder by spray-drying a colloidal solution comprising bismuth citrate, ammonia and a polyhydric alcohol.

Abstract: The radionuclide Tin, Sn-121 in a carrier hydroxide aggregate is disclosed for the treatment of arthritis and, in particular, rheumatoid arthritis of the hands, the interphalangeal joints of the fingers and the metacarpal joints of the hand.The radioactive compound disclosed preferably has a particle size of <90 microns. The beta energy emission associated with Tin, Sn-121 has an energy of 0.38 meV. There are no gamma photons emited during the decay of Tin, Sn-121 to stable Antimony Sb-121. The half life of Tin, Sn-121 is 27.06 hours.The method of preparation of the compound is disclosed along with the method of administration to the patient in need thereof.